Clinical Trials Logo

Heart Failure clinical trials

View clinical trials related to Heart Failure.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT03492788 Terminated - Clinical trials for Heart Failure, Systolic

Optimizing CRT With ECGI

optCRT
Start date: December 28, 2017
Phase: N/A
Study type: Interventional

CRT is delivered from two electrodes on opposite sides of the heart [right (RV) and left ventricle (LV)] delivering stimulation for more efficient heart beats. There is flexibility in the sequence and temporal staggering of the stimulation from these two electrodes with a different optimum for different patients. However, standard techniques to figure out the optimal stimulation strategy like standard 12-lead surface electrical recording (ECG) or routine ultrasound have failed. The investigators have developed ECG imaging (ECGI) with 250 electrode surface recording combined with CT scan to reconstruct high resolution 4-dimensional panoramic electrical maps of the heart. The study seeks to enroll 56 patients undergoing CRT in a clinical trail to evaluate short and long term impact of using ECGI for optimal programming of CRT.

NCT ID: NCT03346278 Terminated - Clinical trials for Myocardial Infarction

Text Message Intervention to Improve Cardiac Rehab Participation

Start date: November 7, 2017
Phase: N/A
Study type: Interventional

Cardiac rehabilitation (CR) is strongly recommended for patients with coronary heart disease. However, patient enrollment and completion of cardiac rehabilitation is low. This study will examine if a mobile phone intervention that uses a text messaging program can successfully promote participation in cardiac rehabilitation.

NCT ID: NCT03314675 Terminated - Heart Failure Clinical Trials

Assessment of Pacing Stimulus Conduction and Latency Measurements in CRT-D Patients

BIO|PULSE
Start date: February 26, 2018
Phase: N/A
Study type: Interventional

The study is designed to collect data on LV latency in CRT-D patients by the CRT-D and compare measurements to 12-lead ECG data

NCT ID: NCT03276728 Terminated - Heart Failure Clinical Trials

Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Subjects and Heart Failure Patients

Start date: August 12, 2016
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of ascending single (Part A) and ascending multiple (Part B) doses of AMG 986 in healthy subjects, who received AMG 986 by constant intravenous (IV) infusion or oral (PO) administration and of ascending multiple PO doses of AMG 986 in heart failure patients (Part C).

NCT ID: NCT03262571 Terminated - Clinical trials for Chronic Heart Failure

Usefulness of Lung Ultrasound in Ambulatory Management of Patients With Chronic Heart Failure

Start date: December 2010
Phase: Phase 3
Study type: Interventional

Purpose. The aim of this study is to evaluate whether lung ultrasound, in addition to physical examination, leads to a reduction of the admission rate for acute decompensated heart failure of patients with chronic heart failure (HF) followed in the outpatients heart failure clinic. Methods. This is a prospective randomized study. The planned sample size consists of 440 patients with chronic HF. The inclusion criteria are: (1) male and female aged between 18 and 90 years (2) signed written informed consent (3) history of HF for at least six months, (4) left ventricular ejection fraction < 45%, (5) adequate medical therapy for HF for at least two months. The exclusion criteria are: (1) concomitant enrollment in other clinical studies, or treatment with experimental drugs or devices within 30 days of clinical assessment, (2) inability to undergo to the planned follow-up and procedures (3) documented pulmonary infections (3) interstitial lung disease and class 4 chronic obstructive pulmonary disease according to GOLD classification. Patients are randomized in two groups: group A, patients undergoing to lung ultrasound and physical examination; and group B, patients undergoing to physical examination only. Patients are evaluated at baseline and after three months with medical history, Quality of Life test, physical examination, blood sample for hematochemical (creatinine, electrolytes, BNP/NTpro-BNP). The diuretic therapy is then optimized according to the presence and severity of B-lines in group A and physical examination in group B. Only patients enrolled in group A undergo to a lung ultrasound examination to assess the extent of pulmonary congestion, through its evidence of B-lines. B-lines originate from the contrast between air-filled structures and water-thickened pulmonary interlobular septa. This leads to linear echogenic vertical artefacts that spread from the pleural layers downwards in the screen. The ultrasound examination is performed with a handheld echocardiography device. The physician carries out a scan of the pulmonary fields, from basal towards mid and apical fields, through the midaxillary line while the patient lies supine. The quantification of B-lines is performed according to their extent over the lung fields. All the information are recorded in dedicated forms. The results are evaluated according to the following criteria. The primary end-point is a significant reduction of hospitalizations for acute decompensated HF in group A during the follow-up period. The secondary end-points are changes of NT-proBNP values, quality of life test (QLT) score and cardiac mortality.

NCT ID: NCT03258060 Terminated - Heart Failure Clinical Trials

CRT In Narrow QRS Heart Failure: Mechanistic Insights From Cardiac MRI And Electroanatomical Mapping

Start date: April 2014
Phase: N/A
Study type: Interventional

Cardiac Resynchronisation Therapy (CRT) is a specialist pacemaker procedure that aims to improve the efficiency of the heartbeat. This treatment is used routinely in patients with heart failure and a delay in electrical conduction across the heart seen on the surface ECG (heart tracing). Also CRT has been seen to improve some heart failure patients with a normal electrical conduction (seen on the ECG as a narrow QRS complex). The investigators aim to see if cardiac MRI can be used to select patients with normal electrical conduction for CRT, therefore expanding the number of people who would stand to benefit from this treatment.

NCT ID: NCT03195660 Terminated - Sleep Apnea Clinical Trials

Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study

CAT-PEF
Start date: June 26, 2017
Phase: N/A
Study type: Interventional

This study is designed to demonstrate feasibility of study conduct and that acceptable adherence to adaptive servo-ventilation (ASV) therapy can be achieved in recently hospitalized HFpEF patients with moderate to severe sleep apnea. All subjects meeting the criteria will receive ASV therapy.

NCT ID: NCT03170219 Terminated - Acute Heart Failure Clinical Trials

Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Study

SUBQ-HF
Start date: April 27, 2018
Phase: Phase 2
Study type: Interventional

To determine if a strategy of early discharge using a novel subcutaneous delivery system for parenteral furosemide can improve clinical outcomes within 30 days of randomization (days alive and outside the hospital) compared to usual care.

NCT ID: NCT03152552 Terminated - Diabetes Mellitus Clinical Trials

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Start date: July 25, 2017
Phase: Phase 2
Study type: Interventional

This was a dose-finding study to evaluate the efficacy, safety and tolerability of 3 different doses of LIK066 compared to placebo or empagliflozin in T2DM patients with heart failure

NCT ID: NCT03102827 Terminated - Clinical trials for Heart Failure,Congestive

High-Flow-Therapy for the Treatment of Cheyne-Stokes-Respiration in Chronic Heart Failure

FLOAT-CS
Start date: February 2, 2017
Phase: Phase 3
Study type: Interventional

To demonstrate the effectiveness and safety of nocturnal ventilation with oxygen (HFT - high-flow-therapy) for the treatment of CSA in patients with HFrEF compared to placebo (patient will breathe ambient air via nasal cannula that is not connected to the high-flow-device).